The ePlex® Blood Culture Identification Panels: Designed to Improve Patient Care and Clinical Outcome

Bloodstream infections are a major cause of mortality and morbidity in hospitalized patients. Rapid diagnosis of bloodstream infections is critical to improving the overall clinical outcomes for septic patients. Several molecular methods exist that rapidly detect microorganisms and antimicrobial resistance genes from positive blood cultures or directly from blood. The ePlex Blood Culture Identification (BCID) Panels are novel multiplex assays for the detection of bacterial and fungal organisms and select determinants associated with antimicrobial resistance in positive blood cultures.

The ePlex BCID multiplex PCR panels use a 3-panel design enabling the broadest inclusivity. The BCID-Gram Positive (BCID-GP) Panel identifies 20 gram-positive bacterial targets, 4 resistance genes, Pan Candida and Pan Gram-Negative targets; the BCID-Gram Negative (BCID-GN) Panel identifies 21 gram-negative bacterial targets, 6 resistance genes, Pan Candida and Pan Gram-Positive targets; and, the BCID-Fungal Pathogen (BCID-FP) Panel identifies 11 Candida and 4 additional fungal targets. Broader inclusivity delivers reduced time to result for more organisms, which may improve patient outcome and can enhance antimicrobial stewardship.

Join this webinar for a discussion of the ePlex BCID Panels (Investigational Use Only) and to see data from an evaluation of the ePlex Blood Culture Identification Panels performed by Dr. Stefan Juretschko, Director, Division of Infectious Disease Diagnostics at Northwell Health System.

Speaker

Stefan Juretschko, PhD, D(ABMM), Director, Division of Infectious Disease Diagnostics at Northwell Health System

Stefan, Juretschko PhD, D(ABMM), serves as the Senior Director of the Division of Infectious Disease Diagnostics at the New York-based Northwell Health Laboratories. He oversees three hospital-based laboratories and a central Core Laboratory with full-service Clinical Microbiology, Mycology, Parasitology, Mycobacteriology, Virology and Molecular Diagnostics, supporting five tertiary, 12 community, three specialty, and two affiliated hospitals, along with more than 600 ambulatory and physician practices.

Message Presenter